...
首页> 外文期刊>The Analyst: The Analytical Journal of the Royal Society of Chemistry: A Monthly International Publication Dealing with All Branches of Analytical Chemistry >A novel liquid biopsy-based approach for highly specific cancer diagnostics: mitigating false responses in assaying patient plasma-derived circulating microRNAs through combined SERS and plasmon-enhanced fluorescence analyses
【24h】

A novel liquid biopsy-based approach for highly specific cancer diagnostics: mitigating false responses in assaying patient plasma-derived circulating microRNAs through combined SERS and plasmon-enhanced fluorescence analyses

机译:一种新的液体活组织检查的高度癌症诊断方法:通过组合SERS和等离子体增强的荧光分析来减轻患者血浆衍生循环微小RNA的虚假反应

获取原文
获取原文并翻译 | 示例
           

摘要

Studies have shown that microRNAs, which are small noncoding RNAs, hold tremendous promise as next-generation circulating biomarkers for early cancer detection via liquid biopsies. A novel, solid-state nanoplasmonic sensor capable of assaying circulating microRNAs through a combined surface-enhanced Raman scattering (SERS) and plasmon-enhanced fluorescence (PEF) approach has been developed. Here, the unique localized surface plasmon resonance properties of chemically-synthesized gold triangular nanoprisms (Au TNPs) are utilized to create large SERS and PEF enhancements. With careful modification to the surface of Au TNPs, this sensing approach is capable of quantifying circulating microRNAs at femtogram/ microliter concentrations. Uniquely, the multimodal analytical methods mitigate both false positive and false negative responses and demonstrate the high stability of our sensors within bodily fluids. As a proof of concept, microRNA-10b and microRNA-96 were directly assayed from the plasma of six bladder cancer patients. Results show potential for a highly specific liquid biopsy method that could be used in point-of-care clinical diagnostics to increase early cancer detection or any other diseases including SARS-CoV-2 in which RNAs can be used as biomarkers.
机译:研究表明,小型非编码RNA的microRNA,作为下一代循环生物标志物,以通过液体活组织检查检测早期癌症检测。已经开发了一种新的固态纳米纳米型传感器,其能够通过组合的表面增强的拉曼散射(SERS)和等离子体增强的荧光(PEF)方法来测定循环微小RORNA。这里,利用化学合成的金三角形纳米棱镜(AU TNP)的独特局部表面等离子体共振性能来产生大的SERS和PEF增强。通过对Au TNP的表面进行仔细修改,这种感测方法能够在汇总/微升浓度下量化循环微小Rna。唯一的是,多模式分析方法减轻了假阳性和假阴性响应,并证明了在体液中的传感器的高稳定性。作为概念证明,MicroRNA-10B和MicroRNA-96直接从六个膀胱癌患者的血浆中测定。结果表明,高度特异性液检方法的潜力可用于治疗点临床诊断,以提高早期癌症检测或任何其他疾病,包括SARS-COV-2,其中RNA可以用作生物标志物。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号